title: [The antihepatoma effect of lyophilized aclacinomycin A polyisobutylcyanoacrylate nanoparticles in vitro and in vivo].
abstract: This paper reports the results of experiments on the antihepatoma effects of live targeted drug delivery system--lyophilized aclacinomycin A polyisobutylcyanoacrylate nanoparticle (ACM-IBC-NP) in vitro and in vivo. The median inhibition concentration were found to be 0.28 micrograms.ml-1 and 0.34 micrograms.ml-1 of lyophilized ACM-IBC-NP and ACM respectively in vitro. The inhibition ratio of colony formation were found to be 99% and 88% of lyophilized ACM-IBC-NP and ACM respectively in vitro. The antihepatoma activity was shown to be significantly concentration dependent. The results showed that lyophilized ACM-IBC-NP and ACM possess strong cytotoxicity on human hepatoma cell 7703, and the cytotoxicity was not significantly different between lyophilized ACM-IBC-NP and ACM in vitro. The model of orthotopic transplantation of human hepatoma in nude mice were used for evaluation of the activity of lyophilized ACM-IBC-NP against hepatoma. The tumor inhibition rate were found to be 86.84% for lyophilized ACM-IBC-NP and 46.69% for ACM. The cell proliferative activity of hepatoma were found to be 20.83% by lyophilized ACM-IBC-NP and 72.50% by ACM. All the results indicate that lyophilized ACM-IBC-NP and ACM have clinical application potential and the antihepatoma activity of lyophilized ACM-IBC-NP was obviously higher than that of ACM.
authors.affiliation: School of Pharmacy, West China University of Medical Sciences, Chengdu.
authors.forename: X H
authors.initials: XH
authors.lastname: Jiang
authors.forename: G T
authors.initials: GT
authors.lastname: Liao
authors.forename: G Q
authors.initials: GQ
authors.lastname: Huang
authors.forename: S H
authors.initials: SH
authors.lastname: Bai
authors.forename: S L
authors.initials: SL
authors.lastname: Yuan
authors.forename: X B
authors.initials: XB
authors.lastname: Zhang
mesh_terms: D015250:Aclarubicin / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D003487:Cyanoacrylates; D016503:Drug Delivery Systems; D004659:Enbucrilate; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008863:Microspheres; D009368:Neoplasm Transplantation; D011108:Polymers; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D003487:Cyanoacrylates; D011108:Polymers; D018809:Proliferating Cell Nuclear Antigen; D015250:Aclarubicin; D004659:Enbucrilate